Pregnenolone sulfate as a modulator of synaptic plasticity
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The neurosteroid pregnenolone sulfate (PregS) acts as a cognitive enhancer and modulator of neurotransmission, yet aligning its pharmacological and physiological effects with reliable measurements of endogenous local concentrations and pharmacological and therapeutic targets has remained elusive for over 20 years. New basic and clinical research concerning neurosteroid modulation of the central nervous system (CNS) function has emerged over the past 5 years, including important data involving pregnenolone and various neurosteroid precursors of PregS that point to a need for a critical status update. Highly specific actions of PregS affecting excitatory N-methyl-D-aspartate receptor (NMDAR)-mediated synaptic transmission and the pharmacological effects of PregS on various receptors and ion channels are discussed. The discovery of a high potency (nanomolar) signal transduction pathway for PregS-induced NMDAR trafficking to the cell surface via a Ca2+- and G protein-coupled receptor (GPCR)-dependent mechanism and a potent (EC50 ~ 2 pM) direct enhancement of intracellular Ca2+ levels is discussed in terms of its agonist effects on long-term potentiation (LTP) and memory. Lastly, preclinical and clinical studies assessing the promnestic effects of PregS and pregnenolone toward cognitive dysfunction in schizophrenia, and altered serum levels in epilepsy and alcohol dependence, are reviewed. PregS is present in human and rodent brain at physiologically relevant concentrations and meets most of the criteria for an endogenous neurotransmitter/neuromodulator. PregS likely plays a significant role in modulation of glutamatergic excitatory synaptic transmission underlying learning and memory, yet the molecular target(s) for its action awaits identification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
Clark, B. J., Wells, J., King, S. R., & Stocco, D. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46930-x · Cited by 1,168
Neurosteroids: endogenous regulators of the GABAA receptor
Belelli, D., & Lambert, J. J. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1703 · Cited by 1,159 · cited 1×
“The reduced metabolites of PREG neurosteroids act as endogenous GABAAR-positive allosteric modulators with high potency (Belelli and Lambert 2005), based upon structure–activity studies.”
BackgroundStAR protein and the regulation of steroid hormone biosynthesis.
Stocco, D. M. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.193 · Cited by 917 · cited 2×
“Evidence for meeting the criteria for neurotransmitter action Synthesis of PregS in vivo The rate-limiting step for neurosteroid production is the transport of cholesterol from the cytoplasm to the mitochondrial matrix (Stocco 2001) by the steroid acute regulatory (StAR) protein (Clark et al. 1994).”
BackgroundBuchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419 · cited 1×
“…(Gaspar et al. 2009), while the NMDAR has been shown to be a validated therapeutic target for glutamatergic dysfunction in depression, schizophrenia, and Alzheimer’s disease (Buchanan et al. 2007; Butterfield and Pocernich 2003; Gaspar et al. 2009; Pilc et al. 2013; Collingridge et al. 2013).”
BackgroundDouble-blind treatment of major depression with dehydroepiandrosterone.
Wolkowitz, O. M., Reus, V. I., Keebler, A., Nelson, N., Friedland, M., Brizendine, L., & Roberts, E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.646 · Cited by 411 · cited 2×
“…(Budziszewska et al. 1998; Hill et al. 2010; Pieribone et al. 2007), anxiety (Crawley et al. 1986; Ströhle et al. 2002), depression, and schizophrenia (Uzunov et al. 1996; Wolkowitz et al. 1999; Khisti et al. 2000; Marx et al. 2006;Girdler et al. 2012;Wong et al. 2012; Zorumski et al. 2013).”
BackgroundNeurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain
Mellon, S. H., & Deschepper, C. F. (1993) · Brain Research · doi:10.1016/0006-8993(93)91332-m · Cited by 398
Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic β cells
Wagner, T. F. J., Loch, S., Lambert, S., Straub, I., Mannebach, S., Mathar, I., Düfer, M., Lis, A., Flockerzi, V., Philipp, S. E., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1801 · Cited by 392
Pregnenolone and its sulfate ester in the rat brain
Corpéchot, C., Synguelakis, M., Talha, S., Axelson, M., Sjövall, J., Vihko, R., Baulieu, E.-E., & Robel, P. (1983) · Brain Research · doi:10.1016/0006-8993(83)90797-7 · Cited by 385 · cited 1×
“…as fetal alcohol spectrum disorder (Zimmerberg et al. 1995), epilepsy (Budziszewska et al. 1998; Hill et al. 2010; Pieribone et al. 2007), anxiety (Crawley et al. 1986; Ströhle et al. 2002), depression, and schizophrenia (Uzunov et al. 1996; Wolkowitz et al. 1999; Khisti et al. 2000; Marx et al.…”
BackgroundThe molecular and cellular biology of enhanced cognition
Lee, Y.-S., & Silva, A. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2572 · Cited by 361 · cited 1×
“The development of cognitive enhancers is urgently needed for the treatment of neurological disorders such as Alzheimer's disease, depression, and schizophrenia that have component symptoms associated with deficits in learning and memory (Lee and Silva 2009).”
Background
Cited by
Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment
Lombardo, S., & Maskos, U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.018 · Cited by 299
Function and organization of the human cytosolic sulfotransferase (SULT) family
Coughtrie, M. W. H. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.05.005 · Cited by 142
“GABAA and NMDA, and other signalling pathways [45,46].”
Locci, A., & Pinna, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13843 · Cited by 132
Neurosteroid Actions in Memory and Neurologic/Neuropsychiatric Disorders
Ratner, M. H., Kumaresan, V., & Farb, D. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00169 · Cited by 96
Self-citationSong, M., Liu, Y., Zhou, J., Shi, H., Su, X., Shao, M., Yang, Y., Wang, X., Zhao, J., Guo, D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115070 · Cited by 32
Metadata
- Authors
- Smith, C. C., Gibbs, T. T., & Farb, D. H.
- Venue
- Psychopharmacology
- Published
- 2014-07-06
- Volume
- 231
- Issue
- 17
- Pages
- 3537-3556
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1963909831
- Cited by
- 60
- References
- 19
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pregnenolone sulfate as a modulator of synaptic plasticity. https://app.cochat.ai/papers/10.1007/s00213-014-3643-x
- The paper
- Smith, C. C., Gibbs, T. T., & Farb, D. H. (2014). Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology. https://doi.org/10.1007/s00213-014-3643-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.